Oric Pharmaceuticals Stock

oricpharma.comHealthcare / BioTech & PharmaFounded: 2014Funding to Date: $173MM

ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer.

Register To Buy and Sell Shares

For more details on financing and valuation for Oric Pharmaceuticals, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Oric Pharmaceuticals’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Oric Pharmaceuticals.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

Jacob Chacko MD
Chief Executive Officer & Board Member
Charles Sawyers MD
Dominic Piscitelli
Chief Financial Officer
Matthew Panuwat
Chief Business Officer
Lori Friedman Ph.D
Chief Scientific Officer
Richard Heyman Ph.D
Co-Founder, Chairman & Board Member
Scott Lowe Ph.D

Board Members

Leo Guthart
Laurence Lasky Ph.D
Richard Scheller Ph.D
Carl Gordon Ph.D
Richard Heyman Ph.D
Peter Svennilson
The Column Group
Jacob Chacko MD

News Highlights

Xconomy: ORIC Pharma Gets $120M in IPO to Advance Drug-Resistant Cancer Therapies
ORIC Pharmaceuticals followed in the footsteps of the other biotechs that have managed to go public this month, selling more shares than it expected for a
ORIC Pharmaceuticals Appoints Dominic Piscitelli as Chief Financial Officer
/PRNewswire/ -- ORIC Pharmaceuticals, a privately held, clinical-stage oncology company focused on developing cancer treatments that address mechanisms of...
ORIC Pharmaceuticals : Announces Completion of $55 Million Mezzanine Financing to Advance Pipeline of Novel Therapies Targeting Cancer Resistance
Updated on: Dec 2, 2023


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.